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Nuclear receptors are DNA-binding transcription factors, the transcriptional function of many of which depends
on the binding of ligands, a feature that distinguishes nuclear receptors from other transcription factors.This
review will summarize recent advances in our knowledge of the interaction between selected nuclear receptors
and their cognate ligands.
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Introduction
Nuclear receptors are DNA-binding transcription factors.
The transcriptional function of most nuclear receptors
depends on the binding of ligands, a feature that
distinguishes nuclear receptors from other transcription
factors.When bound to an activating ligand, nuclear
receptors recruit coactivator proteins such as the Steroid
Receptor Coactivators (SRC-1, 2, and 3) and the
TRAP/DRIP mediator complex via their LXXLL sequence
motifs [McKenna et al., 1999]. In contrast, the binding of
an antagonist destabilizes nuclear receptor/coactivator
complexes, instead promoting interactions with
corepressors such as Nuclear CoRepressor (N-CoR) and
Silencing Mediator for Retinoid and Thyroid hormone
receptors (SMRT) [Hu and Lazar, 2000].
Coactivators generally promote gene transcription,
whereas corepressors repress gene transcription.
Coactivators and corepressors are thus the Yin-Yang
factors that determine the transcriptional functions of
nuclear receptors and subsequent ligand-mediated
physiological responses.The molecular mechanisms of
ligand-mediated recruitment of coactivators or
corepressors are highly conserved across the nuclear
receptor superfamily. In this review, we illustrate the basic
principles of these mechanisms with X-ray structures of
Peroxisome Proliferator-Activated Receptor– α (PPAR-α)
in complex with either an agonist and coactivator or an
antagonist and corepressor.
PPAR-α
PPAR-α is a key factor in fatty acid metabolism, and is
responsible for mediating the lipid-lowering effects of
fibrate drugs [Issemann and Green, 1990]. As a nuclear
receptor, the PPAR-α LBD contains both the ligand
binding and the ligand-dependent transcription activation
function (AF-2), which is located at the extreme C-terminal
end of the domain.The crystal structure of the PPAR-α
LBD (Figure 1A) bound to a potent agonist, GW409544,
reveals that the domain is mainly composed of α -helices
that are folded into a three-layer helical sandwich [Xu et
al., 2001].The middle layer of helices is present in the
upper half of the domain, but absent from the lower half
of the domain, an arrangement that creates the
ligand-binding pocket. Despite the conservation of the
overall fold in nuclear receptors, the size and shape of
the ligand binding pocket varies greatly from receptor to
receptor, thus accounting for the specificity of ligand
recognition and the corresponding signaling pathways.
Figure 1. Structural views of ligand-mediated recruitment of
coactivators and corepressors to nuclear receptors. A, structure of
the PPAR α LBD bound to GW409544 and a SRC-1 coactivator motif
(gold); B, structure of the PPAR α LBD bound to GW6471 and a SMRT
corepressor motif (yellow); C, chemical structures of PPAR α agonist
GW509544 and antagonist GW6471, D, comparison of corepressor and
coactivator peptides bound to PPAR α.
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Review  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 2. Conservation of coactivator and corepressor binding pockets in nuclear receptors. The residues that contact the SMRT corepressor
motif are noted with arrows.
GW409544 agonist and PPAR-α
GW409544 is a synthetic acid that activates PPAR-α with
an EC50 of 5 nM [Xu et al., 2001].The PPAR-α LBD
structure reveals that the acidic group of GW409544
makes a direct hydrogen bond with tyrosine-464 of the
C-terminal AF-2 helix (red helix in Figure 1A), thereby
locking the AF-2 helix in the active conformation.The
same mode of receptor activation is also observed with
PPAR γ and PPAR Δ [Gampe et al., 2000; Nolte et al.,
1998; Xu et al., 1999]. In the case of PPAR γ, mutations
that destabilize the active conformation of the AF-2 helix
result in severe type II diabetes and dyslipidemia.
Interestingly, this defect can be rescued by a potent PPAR
γ agonist, which helps to re-stabilize the active AF-2
conformation [Kallenberger et al., 2003].These results
highlight the important role of ligands and the AF-2 helix
in nuclear receptor regulation.
When the AF-2 helix is positioned in the active
conformation, it contributes a conserved glutamate
residue to form an essential part of a “charge-clamp”
pocket with a lysine from helix 3.The coactivator binds
to nuclear receptor through an LXXLL motif, which adopts
a two-turn α -helix (gold helix in Figure 1A) with the
hydrophobic leucine side-chains docking into the
hydrophobic pocket between the two charge-clamp
residues.The docking of the coactivator helix is further
stabilized by helix-capping interactions with the
charge-clamp residues at both ends of the helix.This
same mode of coactivator binding was also observed in
the previous structures of the PPAR γ homodimer [Nolte
et al., 1998], the RXR/PPAR γ heterodimer [Gampe et
al., 2000], and receptors for thyroid hormone and
estrogens [Darimont et al., 1998; Shiau et al., 1998],
indicating that the charge clamp pocket is the common
mechanism for coactivator recruitment by nuclear
receptors.
GW6471 antagonist and PPAR-α
Corepressors bind to nuclear receptors through an
LXXXIXXXL/I sequence motif.This is similar to the LXXLL
motif of coactivators, suggesting that corepressors might
utilize a binding mode similar to that of coactivators
[Perissi et al., 1999]. Expecting that corepressor
recruitment to PPAR-α would be enhanced by an
antagonist, we used knowledge from agonist-bound PPAR
structures to design an antagonist, GW6471, to facilitate
crystallization with SMRT [Xu et al., 2002].The chemical
structure of GW6471 is similar to that of GW409544
except that the carboxylate group of GW409544 has been
modified into an amide group in GW6741 (Figure 1C). In
its complex with PPAR-α, the GW409544 carboxylate
makes a key interaction with Tyr464 in the AF-2 helix that
is critical for receptor activation.The ethyl amide group
in GW6471 was designed to block this key hydrogen
bond, and to protrude into the volume normally occupied
by Tyr464, thereby displacing the AF2 helix (green helix
in Figure 1B and D).This prevents activation, and
converts the compound from an agonist into an
antagonist, greatly promoting the binding of corepressors
to PPAR-α.
The crystal structure of the PPAR-α LBD bound to the
antagonist GW6471 and a SMRT corepressor motif
reveals several general features of antagonist-mediated
assembly of the receptor/corepressor complex. First, the
corepressor motif adopts a three-turn α -helix (yellow
helix in Figure 1B), instead of the two-turn helix observed
for coactivator motifs. Second, the corepressor-binding
site overlaps the coactivator-binding site, with the
additional helical turn of the corepressor motif extending
into volume normally occupied by the AF-2 helix if it were
in the active conformation.This provides a simple
mechanism that makes coactivator and corepressor
binding mutually exclusive and dependent on the position
of the AF2 helix.Third, the binding of GW6471 pushes
the AF-2 helix out of its active position, opening a larger
binding grove to accommodate the extended corepressor
helix.The repositioning of the AF-2 helix reinforces the
importance of the highly flexible nature of this helix,
allowing its conformation to be modulated by the binding
of small molecules, either agonist or antagonist, to
activate or to repress transcription.
The X-ray structure shows that SMRT makes key
interactions with PPAR-α through the side-chains of its
L+1, I+5 and L+9 residues. Alanine scanning mutagenesis
through the SMRT corepressor motif confirms that these
three core residues are the most critical for corepressor
binding to PPAR-α and TR, especially the I+5 residue.
www.nursa.org  NRS  | 2003 |  Vol. 1 |  DOI: 10.1621/nrs.01004 | Page 2 of 3
Review Nuclear receptor - ligand interactionsIn addition, the PPAR-α residues that make up the
corepressor binding pocket are also highly conserved
across the nuclear receptor family (Figure 2), and the
PPAR-α structure may provide a model for understanding
ligand-mediated recruitment of coactivators and
corepressors in other nuclear receptors.
Conclusion
In summary, ligand-dependent regulation of nuclear
receptors is mediated through the highly mobile AF-2
helix, the position of which determines the ability of
nuclear receptor to recruit coactivators or corepressors.
Both coactivators and corepressor use a short helical
motif to interact with nuclear receptors. In the presence
of an agonist, the AF-2 helix is stabilized in the active
conformation that forms a charge-clamp pocket to
facilitate the binding of coactivator helix. In contrast, the
binding of an antagonist keeps the AF-2 helix out of the
active position, resulting in a larger pocket that
destabilizes coactivator binding but fits better with the
three-turn α -helix formed by the corepressor motif.The
AF-2 helix thus serves as a ligand sensor to regulate
nuclear receptor function. Furthermore, the ability to
modulate the AF-2 helix by ligands has provided a great
opportunity to design various ligands to control the
biological processes mediated by the receptors and their
related disease conditions.
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